Related Experiment Video
Updated: Jul 6, 2025
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus
Shiyang Ma1,2,3,4,5, Fei Zhu1,2,3,4,5, Yizhong Xu1,2,3,4,5
1Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
Human metapneumovirus (HMPV) is one of the main pathogens causing severe respiratory infections in children, as a common cause of immunodeficiency-related deaths in children and elderly individuals, the prevalence of HMPV has been showing an increasing trend during the last years. However, no vaccines or effective treatment plans are available currently. In this present, based on candidate proteins highly associated with viral virulence and has promising protective potential, we screened for immunodominant cytotoxic T cells, helper T cells, and Linear B-cell epitopes from the most promising candidate Fusion protein, together with G, SH, M, and M2. All epitopes were predicted to have strong antigenicity by Vaxijen and pose no potential toxicity, allergenicity, or hormonology to human proteins by Toxinpred, Allerpred, and Blast analysis, meanwhile, high conservancy is demanded to cover different subtypes. adjuvants β-defensin II and Pam2Cys was attached with EAAAK linkers to improve vaccine's efficiency. Then, calculation of physicochemical properties proved the protein vaccine as a product can stably exist in the human body. Besides, we assessed the docking between the vaccine and immune receptors to evaluate its ability to stimulate immune responses, and the dynamic simulation further confirmed that the vaccine can tightly bind with immune receptors, which approved that the construction has the potential to induce strong humoral and cellular immune response. Finally, the vaccine was constructed into a multi-epitope mRNA vaccine, the immune simulations suggest that this is a vaccine candidate for controlling HMPV infection.
Insights
A novel multi-epitope mRNA vaccine candidate targeting human metapneumovirus (HMPV) shows promise for controlling respiratory infections. This vaccine design leverages immunodominant epitopes to elicit strong immune responses against HMPV.
Area of Science:
- Virology and Immunology
- Vaccine Development
Background:
- Human metapneumovirus (HMPV) is a significant cause of severe respiratory infections in children and a contributor to immunodeficiency-related deaths.
- The prevalence of HMPV infections is increasing, yet effective vaccines and treatments are currently unavailable.
Purpose of the Study:
- To design and computationally evaluate a novel multi-epitope vaccine candidate against HMPV.
- To identify and characterize immunodominant epitopes from key HMPV proteins for vaccine construction.
Main Methods:
- Screening of immunodominant cytotoxic T cells, helper T cells, and linear B-cell epitopes from HMPV Fusion, G, SH, M, and M2 proteins.
- In silico analysis using Vaxijen, Toxinpred, Allerpred, and Blast to predict antigenicity, toxicity, allergenicity, and conservancy.
- Computational modeling, including molecular docking and dynamic simulations, to assess vaccine-receptor interactions and immune response potential.
Main Results:
- Identified highly antigenic, non-toxic, non-allergenic, and conserved epitopes suitable for vaccine development.
- Computational assessments indicated the vaccine construct's stability and potential to induce strong humoral and cellular immune responses.
- The final multi-epitope mRNA vaccine candidate demonstrated promising immune stimulation in silico simulations.
Conclusions:
- The developed multi-epitope mRNA vaccine is a potential candidate for controlling HMPV infections.
- This study provides a computational framework for designing effective epitope-based vaccines against viral pathogens.
